These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30301385)

  • 1. Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase.
    Konishi K; Minematsu T; Nagasaka Y; Tabata K
    Xenobiotica; 2019 Aug; 49(8):912-921. PubMed ID: 30301385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
    Konishi K; Minematsu T; Nagasaka Y; Tabata K
    Biopharm Drug Dispos; 2019 May; 40(5-6):176-187. PubMed ID: 30985942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
    Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
    J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulation.
    Klose M; Cristofoletti R; Silva CM; Mangal N; Turgeon J; Michaud V; Lesko LJ; Schmidt S
    Eur J Pharm Sci; 2024 Mar; 194():106689. PubMed ID: 38171419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
    Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
    Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions.
    Kilford P; Khoshaein N; Southall R; Gardner I
    Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):699-710. PubMed ID: 35840839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist.
    Takusagawa S; Yajima K; Miyashita A; Uehara S; Iwatsubo T; Usui T
    Xenobiotica; 2012 Oct; 42(10):957-67. PubMed ID: 22509825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo.
    Johnson TN; Howgate EM; de Wildt SN; Turner MA; Rowland Yeo K
    Drug Metab Dispos; 2023 Aug; 51(8):1035-1045. PubMed ID: 37169511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction.
    Takeda S; Ishii Y; Iwanaga M; Nurrochmad A; Ito Y; Mackenzie PI; Nagata K; Yamazoe Y; Oguri K; Yamada H
    Mol Pharmacol; 2009 Apr; 75(4):956-64. PubMed ID: 19158361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Modeling to Predict the Impact of Liver Cirrhosis on Glucuronidation via UGT1A4 and UGT2B7/2B4-A Case Study with Midazolam.
    Ozbey AC; Keemink J; Wagner B; Pugliano A; Krähenbühl S; Annaert P; Fowler S; Parrott N; Umehara K
    Drug Metab Dispos; 2024 Jun; 52(7):614-625. PubMed ID: 38653501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid.
    Callegari E; Lin J; Tse S; Goosen TC; Sahasrabudhe V
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):127-136. PubMed ID: 33314761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir.
    Stader F; Battegay M; Marzolini C
    Clin Pharmacol Ther; 2021 Nov; 110(5):1231-1239. PubMed ID: 33626178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions.
    Li T; Zhou S; Wang L; Zhao T; Wang J; Shao F
    J Pharmacokinet Pharmacodyn; 2024 Aug; 51(4):367-384. PubMed ID: 38554227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
    Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
    Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.
    Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M
    Clin Pharmacokinet; 2017 Apr; 56(4):409-420. PubMed ID: 27599706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
    Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of Cytochrome P450 3A4 Function by UDP-Glucuronosyltransferase 2B7 through a Protein-Protein Interaction: Cooperative Roles of the Cytosolic Carboxyl-Terminal Domain and the Luminal Anchoring Region.
    Miyauchi Y; Nagata K; Yamazoe Y; Mackenzie PI; Yamada H; Ishii Y
    Mol Pharmacol; 2015 Oct; 88(4):800-12. PubMed ID: 26243732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.
    Asaumi R; Toshimoto K; Tobe Y; Hashizume K; Nunoya KI; Imawaka H; Lee W; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):186-196. PubMed ID: 29368402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.